|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1997-5-1
|
|
pubmed:abstractText |
We have investigated the autocrine regulation of insulin-like growth factor-II (IGF-II) signaling by the insulin-like growth factor-I receptor (IGF-IR) and the insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-IIR) in MCF-7 breast cancer cells, employing retroviruses encoding both IGF-I, IGF-II, and IGF-I and II mutants with reductions in affinity for either the IGF-IR or the IGF-IIR. These studies revealed reciprocal roles for IGF-IR and IGF-IIR affinity in the regulation of autocrine IGF-II activity. IGF-IR affinity was required for serum-free proliferation but also for efficient IGF-II secretion. In contrast, cellular proliferation, receptor tyrosine kinase-dependent signaling, and extracellular IGF-II protein accumulation were all reduced in the presence of IGF-IIR affinity. Inhibition of IGF-II signaling appeared to be the sole consequence of IGF-IIR affinity, as no cellular responses attributable to selective IGF-IIR binding by a reduced IGF-IR affinity IGF-II mutant could be detected. By operating as an IGF-II antagonist, the IGF-IIR has tumor suppressor-like properties, a suggestion consistent with reports of loss of heterozygosity at the IGF-IIR locus in a variety of human malignancies.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Culture Media, Serum-Free,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor II,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0888-8809
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
286-97
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:8833657-Amino Acid Sequence,
pubmed-meshheading:8833657-Binding Sites,
pubmed-meshheading:8833657-Breast Neoplasms,
pubmed-meshheading:8833657-Carcinoma, Ductal, Breast,
pubmed-meshheading:8833657-Cell Division,
pubmed-meshheading:8833657-Culture Media, Serum-Free,
pubmed-meshheading:8833657-Extracellular Space,
pubmed-meshheading:8833657-Female,
pubmed-meshheading:8833657-Humans,
pubmed-meshheading:8833657-Insulin-Like Growth Factor I,
pubmed-meshheading:8833657-Insulin-Like Growth Factor II,
pubmed-meshheading:8833657-Molecular Sequence Data,
pubmed-meshheading:8833657-Neoplasm Proteins,
pubmed-meshheading:8833657-Neoplasms, Hormone-Dependent,
pubmed-meshheading:8833657-Protein Binding,
pubmed-meshheading:8833657-RNA, Messenger,
pubmed-meshheading:8833657-Receptor, IGF Type 1,
pubmed-meshheading:8833657-Receptor, IGF Type 2,
pubmed-meshheading:8833657-Recombinant Fusion Proteins,
pubmed-meshheading:8833657-Signal Transduction,
pubmed-meshheading:8833657-Transfection
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.
|
|
pubmed:affiliation |
Vincent T Lombardi Cancer Center, Georgetown University Medical Center, Washington, D.C, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
